The SATELLITE study, which concluded early after randomising 41 patients, established the safety of the myeloperoxidase inhibitor AZD4831 in patients with HF and LV EF of ≥40%; it also demonstrated a more than 50% decrease in myeloperoxidase activity from baseline [61]. This evidence concerns the gene MPO and hydrops fetalis.